56 related articles for article (PubMed ID: 26942553)
1. Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer.
Sharma S; Mahajan SD; Chevli K; Schwartz SA; Aalinkeel R
Crit Rev Ther Drug Carrier Syst; 2023; 40(4):69-100. PubMed ID: 37075068
[TBL] [Abstract][Full Text] [Related]
2. Engineering HEK293T cell line by lentivirus to produce miR34a-loaded exosomes.
Sarkami SA; Molavipordanjani S; Abediankenari S; Akhtari J; Gill P; Ghalehnoei H; Lemoni SK
Mol Biol Rep; 2023 Nov; 50(11):8827-8837. PubMed ID: 37658928
[TBL] [Abstract][Full Text] [Related]
3. Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma.
Sciandra M; De Feo A; Parra A; Landuzzi L; Lollini PL; Manara MC; Mattia G; Pontecorvi G; Baricordi C; Guerzoni C; Bazzocchi A; Longhi A; Scotlandi K
J Cell Commun Signal; 2020 Sep; 14(3):335-347. PubMed ID: 32504411
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer.
Bertoli G; Cava C; Castiglioni I
Int J Mol Sci; 2016 Mar; 17(3):421. PubMed ID: 27011184
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches.
Doldi V; Pennati M; Forte B; Gandellini P; Zaffaroni N
Cell Mol Life Sci; 2016 Jul; 73(13):2531-42. PubMed ID: 26970978
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.
Michalska M; Schultze-Seemann S; Bogatyreva L; Hauschke D; Wetterauer U; Wolf P
Oncotarget; 2016 Apr; 7(16):22531-42. PubMed ID: 26968813
[TBL] [Abstract][Full Text] [Related]
7. Multifaceted and personalized therapy of advanced prostate cancer.
Thakur MK; Vaishampayan U
Curr Opin Oncol; 2016 May; 28(3):222-31. PubMed ID: 26992199
[TBL] [Abstract][Full Text] [Related]
8. MiR-218 impedes IL-6-induced prostate cancer cell proliferation and invasion via suppression of LGR4 expression.
Li F; Gu C; Tian F; Jia Z; Meng Z; Ding Y; Yang J
Oncol Rep; 2016 May; 35(5):2859-65. PubMed ID: 26986507
[TBL] [Abstract][Full Text] [Related]
9. An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells.
Peitzsch C; Cojoc M; Hein L; Kurth I; Mäbert K; Trautmann F; Klink B; Schröck E; Wirth MP; Krause M; Stakhovsky EA; Telegeev GD; Novotny V; Toma M; Muders M; Baretton GB; Frame FM; Maitland NJ; Baumann M; Dubrovska A
Cancer Res; 2016 May; 76(9):2637-51. PubMed ID: 26984757
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in prostate cancer: Functional role as biomarkers.
Kanwal R; Plaga AR; Liu X; Shukla GC; Gupta S
Cancer Lett; 2017 Oct; 407():9-20. PubMed ID: 28823964
[TBL] [Abstract][Full Text] [Related]
11. Printed Electrochemical Strip for the Detection of miRNA-29a: A Possible Biomarker Related to Alzheimer's Disease.
Miglione A; Raucci A; Amato J; Marzano S; Pagano B; Raia T; Lucarelli M; Fuso A; Cinti S
Anal Chem; 2022 Nov; 94(45):15558-15563. PubMed ID: 36318963
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression
Yang X; Shang P; Yu B; Jin Q; Liao J; Wang L; Ji J; Guo X
Acta Pharm Sin B; 2021 Sep; 11(9):2819-2834. PubMed ID: 34589399
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer.
Akoto T; Bhagirath D; Saini S
Cancer Drug Resist; 2020; 3(4):804-818. PubMed ID: 33426506
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Potential of MicroRNA Let-7c as a Therapeutic for Prostate Cancer.
Mulholland EJ; Green WP; Buckley NE; McCarthy HO
Mol Ther Nucleic Acids; 2019 Dec; 18():927-937. PubMed ID: 31760377
[TBL] [Abstract][Full Text] [Related]
15. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic roles of microRNAs in hepatocarcinogenesis: A study of thioacetamide with multiple doses and time-points of rats.
Dweep H; Morikawa Y; Gong B; Yan J; Liu Z; Chen T; Bisgin H; Zou W; Hong H; Shi T; Gong P; Castro C; Uehara T; Wang Y; Tong W
Sci Rep; 2017 Jun; 7(1):3054. PubMed ID: 28596526
[TBL] [Abstract][Full Text] [Related]
17. MiRNA 34a: a therapeutic target for castration-resistant prostate cancer.
Chalanqui MJ; O'Doherty M; Dunne NJ; McCarthy HO
Expert Opin Ther Targets; 2016 Sep; 20(9):1075-85. PubMed ID: 26942553
[TBL] [Abstract][Full Text] [Related]
18. Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone.
Fradet A; Bouchet M; Delliaux C; Gervais M; Kan C; Benetollo C; Pantano F; Vargas G; Bouazza L; Croset M; Bala Y; Leroy X; Rosol TJ; Rieusset J; Bellahcène A; Castronovo V; Aubin JE; Clézardin P; Duterque-Coquillaud M; Bonnelye E
Oncotarget; 2016 Nov; 7(47):77071-77086. PubMed ID: 27776343
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
